News 15 mai 2024 Allegria Therapeutics raises 3.5 million dollars in seed financing round Allegria Therapeutics has received seed funding of 3.5 million dollars from the founding investor Forty51 Ventures. The biotech startup is develo...
Aktuell 15 mai 2024 Allegria Therapeutics nimmt 3,5 Millionen Dollar in Seed-Runde ein Allegria Therapeutics hat eine Seed-Finanzierung von 3,5 Millionen Dollar durch den Gründungsinvestor Forty51 Ventures erhalten. Das Biotech-Star...
News 22 mai 2024 CUTISS secures 25 million Swiss francs from investors CUTISS has closed a first Series C financing round in the amount of 25 million Swiss francs. With this, the life sciences company with a focus on...
News 01 mar 2024 Idorsia enters collaboration with Viatris The biotech company Idorsia from the canton of Basel-Landschaft and the North American pharmaceutical company Viatris are collaborating on the de...
Unternehmerreisen Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing 24 jun 2024–28 jun 2024 China
Aktuell 01 mar 2024 Idorsia vereinbart Kooperation mit Viatris Das Biotech-Unternehmen Idorsia und der nordamerikanische Pharmakonzern Viatris arbeiten bei der Entwicklung zweier Phase 3-Medikamente von Ido...
SWISS Pavilion SWISS BIOTECH Pavilion @ BIO-Asia Taiwan 2024 24 jul 2024–28 jul 2024 Nangang District Taiwan
Actualités 19 out 2023 Nouveaux fonds pour le traitement de régénération tissulaire de Mimix Biotherapeutics La société biennoise Mimix Biotherapeutics a annoncé la clôture d’un important tour d’investissement, auquel ont participé des investisseurs euro...
News 25 abr 2024 Swiss biotech achieves record revenues in 2023 Swiss biotech companies generated record revenues of 7.3 billion Swiss francs in 2023, while capital investments rose 50 per cent year on year to...
Fact-Finding Mission Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing 24 jun 2024–28 jun 2024 China
SWISS Pavilion SWISS BIOTECH Pavilion @ BIO-Asia Taiwan 2024 24 jul 2024–28 jul 2024 Nangang District Taiwan